Creating a Framework for Treating Autoimmune Gastritis-The Case for Replacing Lost Acid
- PMID: 38474790
- PMCID: PMC10934127
- DOI: 10.3390/nu16050662
Creating a Framework for Treating Autoimmune Gastritis-The Case for Replacing Lost Acid
Abstract
Autoimmune gastritis (AIG) is characterized by the destruction of gastric parietal cells, resulting in hypochlorhydria and eventual achlorhydria, as oxyntic glands in the corpus are destroyed and become atrophic. The permanent loss of gastric acid has many impacts-both theoretical and documented. The most concerning of these are hypergastrinemia and increased N-nitroso compounds, both of which increase the risk of gastric cancers. While known deficiencies of B12 and iron are often replaced in AIG, acid is not. Moreover, patients with AIG are often prescribed acid suppression for a stomach that is decidedly no longer acidic, worsening the sequelae of gastric atrophy. Betaine hydrochloride (BHCL) is a short-acting acidifying agent, available over the counter in capsule form. Mealtime acid supplementation has an historic basis and could ameliorate many AIG-related gastrointestinal symptoms. Theoretically, acidification could also reduce the potential for hypergastrinemia and the production of N-nitroso compounds, consequently reducing the risk of gastric cancers. Supplemental vitamin C may also help in preventing gastric N-nitroso formation, regardless of the gastric pH. This narrative review describes the functions of gastric acid in gastrointestinal and immune health, documents the effects of hypochlorhydria in AIG, and proposes potential options for safely re-establishing the acid milieu of the stomach for patients with AIG.
Keywords: B12 deficiency; H2 receptor antagonists; atrophic gastritis; autoimmune gastritis; betaine hydrochloride; hypochlorhydria; iron deficiency; pernicious anemia; proton pump inhibitors; vitamin C.
Conflict of interest statement
L.T. declares no conflicts of interest. A.M. is a Scientific Advisor and shareholder of COBALZ Limited. B.R.H.W declares the following interests: consultation for Novo Nordisk on GLP1 scientific data and results, and involved in a Novo Nordisk post-marketing surveillance study on semaglutide use in type 2 diabetes; speaker honorarium from Springer MedNet, for a presentation on new insight into genetics and genomics in diabetes diagnosis and treatment; scientific adviser for a healthcare start-up, Nuevo Care, initiating a dedicated clinic for individuals with B12 deficiency; scientific adviser for a digital health start-up, Ancora Health, offering preventive health programs; member of the Post-Graduate Education Committee of the European Association for the Study of Diabetes; coordinator/organizer for Post-Graduate Educations and Webinars, Diabetes (Alpha Omega Congress) & Endocrinology (BIG5 Endocrinology course); and member of the editorial board of the
References
-
- Lahner E., Carabotti M., Annibale B. Atrophic Body Gastritis: Clinical Presentation, Diagnosis, and Outcome. EMJ Gastroenterol. 2017;6:75–82. doi: 10.33590/emjgastroenterol/10314623. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical